SummaryA 65-year-old obese Caucasian woman presented with symptomatic postprandial
hypoglycemic episodes, resolution of symptoms with carbohydrate intake and
significantly elevated anti-insulin antibody levels. She did not have any evidence
for the use of oral antidiabetic medications, insulin, herbal substances, performing
strenuous exercise or history of bariatric surgery. Fingerstick blood glucose
readings revealed blood sugar of 35 mg/dL and 48 mg/dL, when she had
these symptoms. Her medical history was significant for morbid obesity,
hypothyroidism and gastro esophageal reflux disease. Her home medications included
levothyroxine, propranolol and omeprazole. A blood sample obtained during the
symptoms revealed the following: fingerstick blood sugar 38 mg/dL, venous
blood glucose 60 mg/dL (normal (n):
70–99 mg/dL), serum insulin 202 IU/mL (n:
<21), proinsulin 31.3 pmol/L (n: <28.9), C-peptide
8 ng/mL (n: 0.9–7), beta-hydroxybutyrate
0.12 mmol/L (n: 0.02–0.27) anti-insulin antibody
>45.4 U/mL (n: <0.4). The result obtained while
screening for serum sulfonylurea and meglitinides was negative. The repeated episodes
of postprandial hypoglycemia associated with significantly elevated anti-insulin
antibodies led to a diagnosis of insulin antibody syndrome (IAS). Significant
improvement of hypoglycemic symptoms and lower anti-insulin antibody levels
(33 U/mL) was noted on nutritional management during the following 6 months.
Based on a report of pantoprazole-related IAS cases, her omeprazole was switched to a
H2 receptor blocker. She reported only two episodes of hypoglycemia, and anti-insulin
antibody levels were significantly lower at 10 U/mL after the following
12-month follow-up.Learning points:Initial assessment of the Whipple criteria is critical to establish the
clinical diagnosis of hypoglycemia accurately.Blood sugar monitoring with fingerstick blood glucose method can provide
important information during hypoglycemia workup.Autoimmune hypoglycemia is a rare cause of hypoglycemia, which can be
diagnosed on high index of clinical suspicion and systematic
evaluation.